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 1 
Chapter 2 
Mental Health 
Martin Knapp and Valentina Iemmi 
 
Mental health issues can emerge at any age, with incidence particularly 
common in childhood and young adulthood. The personal and 
economic consequences can last the life-course, and spillover into 
family and wider community impacts. Mental health issues are among 
the most challenging of all illnesses because of the breadth, durability 
and complexity of impact.  
We describe prevalence, mortality and disability, and discuss 
challenges arising in the mental health field, each with economic 
implications. We discuss issues that arise in financing mental health 
interventions, and report expenditure levels. Numerous methodological 
and practical challenges arise when conducting economic evaluation in 
the mental health field. We describe how evidence from cost-
effectiveness and other analyses contribute to better resource utilization 
decisions. 
Throughout the chapter we argue how most mental health problems are 
complicated, and have many negative and often distressing 
consequences for the individuals who are unwell, their families, and the 
wider society. This complexity often makes them expensive, and the 
durability and wide sphere of impact add to the economic 
consequences. Given the pervasive scarcity of resources, decision-
makers must think through the economic case for strategies or 
treatments that might address mental health needs.  
 
1.   Introduction 
Mental health issues can emerge at any age, but are particularly likely 
to become problematic between childhood and young adulthood. They 
often have highly significant consequences across much of the life-
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course, not only for the individual, but also for their family and the wider 
community. Indeed, mental health issues are among the most challenging 
of all health problems because of the breadth, durability and indeed 
complexity of their impacts.  
The effects of poor mental health may start even before life begins: 
maternal mental illness during pregnancy or in the immediate period 
after giving birth can negatively affect a child’s later emotional, 
behavioral and intellectual development. Emotional and behavioral 
problems that develop in childhood often continue into adolescence and 
can lead to difficulties that stretch long into adulthood. Similarly, 
because the most common age of onset of psychoses such as 
schizophrenia and bipolar disorder is in late adolescence and early 
adulthood, the longer-term consequences of these usually very serious 
illnesses can be especially marked over much of adult life because so 
many key investments and decisions are made in the teenage years that 
shape future careers, personal relationships and social roles. But mental 
health problems can also emerge later in life, as a result of traumatic 
experiences, major losses such as bereavement, stresses in the workplace, 
strained inter-personal relationships, or economic difficulties such as 
sudden unemployment or unsecured debt. And one of the most 
challenging of mental health problems is dementia, which in the vast 
majority of cases does not develop until old age.  
We return to some of these topics later – the breadth and durability of 
impacts, for example – and also discuss associations that may indicate 
adverse influences that run in the opposite direction. For example, people 
with mental health problems are more likely to smoke, be overweight, 
have disrupted education, be unemployed, take time off work for health 
reasons, fall into poverty, or find themselves in the criminal justice 
system. It has been shown repeatedly that major mental disorders are 
associated with premature mortality, and there is of course the link 
between some mental illnesses, self-harm and suicide.  
In the next section of the chapter we provide introductory information 
on mental illness, including prevalence, mortality and disability. In 
section 3 we discuss a series of challenges that arise in the mental health 
field: for policy formulation, for healthcare and related practice, and for 
research to support decisions in these areas. We discuss a series of 
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‘economic opportunities and challenges’. Between them, they reflect the 
key characteristics of mental illness: distressing and disabling symptoms 
that are often chronic if untreated; high rates of comorbidity with other 
mental health issues and a range of chronic physical health problems; 
effects on many aspects of individuals’ lives, with consequences for a 
range of public and private budgets; spillover effects on other people, 
especially family members but also in the wider community; disrupted 
employment and work-related difficulties; associations with antisocial 
behavior, substance misuse and crime; links to self-harm and suicide; 
widespread stigma, discrimination and victimization; and strong 
associations with socioeconomic disadvantage and inequalities. 
In section 4, we discuss how mental health interventions might be 
financed. Other chapters in this book have already discussed health 
financing (for example, see chapter XX) and we do not attempt 
comprehensive coverage of the topic; rather, we consider the particular 
issues that arise in the mental health field. We also describe evidence on 
levels of expenditure on mental health interventions. 
We then turn to economic evaluation in section 5, and the 
methodological questions and practical tasks that arise in the mental 
health field, particularly those stemming from the challenges in section 3. 
We discuss how economic arguments can support the case for prevention 
and treatment by describing how evidence from cost-effectiveness and 
other analyses contributes to better decisions about resource use. In the 
final section we make some concluding comments, highlighting the main 
public policy themes that emerge from our examination of the mental 
health area. 
2.   Prevalence, Mortality, Disability  
2.1.  Prevalence 
Mental health problems can be categorized in a number of ways, but the 
distinction is often made between common mental disorders and more 
severe mental disorders. The former include illnesses such as depression, 
generalized anxiety disorder, panic disorder, obsessive-compulsive 
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disorder and post-traumatic stress disorder. The prevalence of common 
mental disorders varies slightly between countries, but is in the range 
15% to 20% of the adult population.
1,2
 So-called severe or serious mental 
health problems – although, of course, many people with depression and 
some anxiety disorders would periodically be experiencing serious 
impairment and distress – include schizophrenia and bipolar disorder 
(sometimes still referred to as ‘manic depression’). The combined 
prevalence of these severe mental disorders is between 2% and 3%, 
although again there can be (small) inter-country differences.  
Other conditions included within the set of disorders conventionally 
seen as mental illnesses are alcohol and drug (substance) abuse, suicide 
and suicidal ideation. The World Health Organization (WHO) 
additionally includes epilepsy as a mental disorder for the purposes of its 
monitoring and advisory activities, although this is not a universally 
accepted convention and we will not discuss epilepsy further in this 
chapter. We will also say little about developmental disorders such as 
intellectual disabilities, although many people with these disorders will 
have comorbid depression or anxiety, and also a greater likelihood of 
developing dementia. 
The classification of mental illnesses is different in childhood, in part 
because of the difficulty of making a diagnosis and in part because some 
disorders tend not to emerge until adolescence or early adulthood. 
Approximately 6% of children and young people aged under 18 years 
have behavioral problems adjudged serious enough to be classified as 
psychiatric disorders.
3
 About 4% of children and young people have 
emotional disorders, but again it is not always straightforward to decide 
when the problems experienced are ‘serious enough’ to warrant 
psychiatric diagnosis. This is obviously not a trivial matter, since 
diagnosis can be stigmatizing. But it is often the gateway to treatment, 
and in some countries may trigger family eligibility for free services or 
income supplements. 
In old age new mental health problems may emerge, in particular the 
various conditions grouped under the umbrella term ‘dementia’, the most 
common being Alzheimer’s disease. Dementia prevalence has a steep 
gradient with age: between 1% and 2% for people aged 65-69 years, but 
22% for men and 30% for women for those aged 90 and above.
4
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Dementia is however not exclusively a problem of old age, since younger 
adults can develop this devastating disease, although prevalence is very 
low before age 60. Much policy and public attention is now being 
focused on dementia because the world’s population is aging rapidly, so 
that there are considerably more people with dementia today than ever 
before, and the number globally will almost double by 2030.
5
 There is 
currently no cure for any of the dementias. Even though there have been 
indications recently that the age-specific prevalence rate might be 
slowing slightly,
6,7
 the total number of people with dementia worldwide 
will still grow rapidly over coming decades unless a disease-modifying 
treatment is found. 
2.2.  Disability 
The consequences of any health problem can be assessed in a number 
of ways, most obviously by describing the symptoms, the impacts on an 
individual’s ability to lead a ‘normal’ life (in terms of independence and 
employment, for instance), and the associated deterioration in quality of 
life. Symptoms are illness-specific and this makes it hard to make 
comparisons or conduct aggregations across different illnesses, and so 
generic metrics for comparison and aggregation have been suggested for 
disability, health-related quality of life and cost. 
The most recent iteration of global burden of disease calculations – 
couched in disability terms – has been generated by the Global Burden of 
Diseases, Injuries, and Risk Factors Study 2010, and includes figures for 
twenty mental and substance use disorders.
8
 Figures for each disorder are 
reported in terms of years of life lost to premature mortality (YLLs), 
years lived with disability (YLDs), and disability-adjusted life years 
(DALYs), which are the sum of YLDs and YLLs. Estimates are adjusted 
for comorbidity. 
Globally in 2010, and aggregated over all mental and substance use 
disorders, the total impact was 184 million DALYs, equivalent to 7·4% 
of the total burden of disease (i.e. DALYs for all health problems 
worldwide). Most of this burden came from years lived with disability 
(175 million YLDs) – equivalent to 23% of the overall total, and the 
leading cause of YLDs worldwide – rather than mortality (9 million 
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YLLs; less than 1% of the overall total). Within the total for mental and 
substance use disorders, depressive disorders made the single largest 
contribution (41% of DALYs associated with these disorders). The next 
largest contributors were: anxiety disorders (15%), illicit drug use 
disorders (11%), alcohol use disorders (10%), schizophrenia (7%), 
bipolar disorder (7%), pervasive developmental disorders (mainly 
autism, 4%), childhood behavioral disorders (3%) and eating disorders 
(1%). The burden associated with mental and substance use disorders has 
grown considerably over time: an increase of 38% between 1990 and 
2010, mostly driven by population growth and ageing, rather than 
changes in age-specific prevalence rates.
8
 Both total and proportional 
burdens are expected to continue to grow over coming decades, 
particularly in low- and middle-income countries (LAMICs). 
One of the important conclusions to draw from this work – and from 
similar work conducted on a smaller scale in individual countries – is 
that the personal and societal impacts of mental health problems cannot 
be adequately gauged from their effects on mortality, but need to be 
understood mainly in terms of their deleterious effects on quality of life 
(broadly interpreted).  
This high disease burden obviously follows from the high prevalence 
and chronic nature of most mental disorders, given that few can currently 
be cured. Not surprisingly, there are also high associated costs (as we 
describe in section 3.3 below). But there are also wide gaps between the 
underlying prevalence and the rate of diagnosis and treatment, especially 
in LAMICs. A few years ago the World Health Organization estimated 
that the proportion of people with serious mental illness who had 
received no treatment in the previous 12 months was between 76% and 
85% in the LAMICs they looked at.
9
 But even in high-income countries, 
the proportion not being treated was generally between 35% and 50%. 
An initiative led by WHO, with buy-in from international donors and 
clinical and academic communities – the Mental Health Gap Action 
Program (mhGAP) – is actively encouraging strategic policy-makers 
across the world to address this major problem of untreated morbidity. 
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3.   Challenges Associated with Mental Illness  
The inherent characteristics of most mental illnesses – many of which 
would be seen as quite complicated and challenging – have a range of 
direct and indirect economic implications. 
3.1.  Enduring Impacts 
Effective treatment of mental health problems will often considerably 
reduce or perhaps completely remove symptoms. However, chronicity of 
the underlying condition remains the usual pattern of illness, and given 
that incidence is often in the formative years of childhood or 
adolescence, the adverse consequences will often extend long into adult 
life. Moreover, as noted above, quite high proportions of people with 
mental health problems do not have their symptoms recognized or 
adequately treated. The effects of this neglect could obviously include 
poor health-related quality of life for those individuals, but also 
antisocial and criminal behavior and substance misuse (often associated 
with behavioral problems in childhood and perhaps with psychosis), 
unemployment, poor workplace experiences (and hence absenteeism and 
presenteeism), poverty and social exclusion. 
Each of these consequences could generate high costs over extended 
periods. For example, Scott et al
10
 looked at follow-up data on a sample 
of 28-year olds whose behavioral and emotional needs (and many other 
characteristics) had been studied at age 10. For this London (UK) 
sample, conduct disorder in childhood (a psychiatric diagnosis; found for 
the most antisocial 3% of the children in the study) and conduct 
problems (found for the next 9%) were predictive of considerably higher 
service-related costs between ages 10 and 28, particularly costs of 
criminal justice contacts. Costs for the conduct disorder group were 
almost ten times higher than those for the group with no mental health 
problems. Child and adolescent mental health services in the UK in the 
early 1970s – when this sample were first studied – were under-
developed and under-resourced, and so these huge cost differences in 
early adulthood probably represent what happens when childhood 
behavioral problems go untreated. 
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Another London cohort study, which started collecting data on a 
group of boys a decade later than the group included in the Scott et al 
study, also found that conduct problems and hyperactivity at age 6-7 
years were associated with high service-related costs (again, especially 
criminal justice costs) twenty years later, but the difference compared to 
boys without mental health problems was smaller.
11
 Given these time 
trajectories there is clearly the potential for good and timely treatment to 
confer positive health and economic benefits over many years too.
12 
Childhood mental health problems also commonly lead to 
employment difficulties in adulthood. Goodman et al
13
 used birth cohort 
data for over 17,000 children born in Britain in one week in 1958 to 
show large effects on earnings, labor supply and other sources of family 
income by age 50 associated with childhood psychological problems. 
Adulthood economic cost related to childhood mental disorders was 
much greater than the cost related to physical illnesses: the impacts of 
poor mental health appeared to occur earlier in adulthood compared to 
the poor physical health. Broadly similar findings emerged from another 
British birth cohort: conduct disorder, attention deficit hyperactivity 
disorder and anxiety problems at age 10 were all associated with worse 
employment-related outcomes at age 30. But there was one important 
exception: boys with conduct disorder in childhood had significantly 
higher earnings than boys without conduct disorder, even after adjusting 
for all relevant covariates.
14
 
A long-term American follow-up study charted the impacts of 
childhood psychological conditions including depression and substance 
abuse up to 40 years later using data from the US Panel Study of Income 
Dynamics (PSID).
15
 The authors followed groups of siblings and their 
parents in an attempt to adjust for some of the covariates that 
compromise this kind of research; they also adjusted for physical health 
in childhood. Childhood psychological problems were strongly 
predictive of poorer educational accomplishments, worse employment 
patterns, lower family household income and assets, and a lower 
probability of being married.  
Buescher et al
16
 calculated the annual and lifetime costs of autism 
spectrum disorders (ASD), covering healthcare, education, social care, 
special housing, community services, social security benefits, and lost 
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employment (productivity losses) for individuals with ASD and their 
families. They compared these costs between the UK and USA, finding 
that the lifetime cost of supporting someone with an ASD who also has 
intellectual disability (IQ below 70) was $2.4 million in the US and £1.5 
million ($2.2 million) in the UK. For someone with an ASD but without 
intellectual disability (e.g. with Asperger’s Syndrome) these lifetime 
costs were $1.4 million (US) and £0.92 million (UK; $1.4 million). The 
similarities in total costs between the two countries were quite striking, 
although underlying patterns of service support differ.  
As noted earlier, the most common age of onset of psychosis is 
adolescence or early adulthood, which can therefore seriously disrupt 
education and post-school training, leading to poor educational outcomes 
and poor longer-term employment prospects. The longer the duration of 
untreated psychosis the worse the health and other outcomes for 
individuals, including a higher risk of suicide. One systematic review 
found a completed suicide rate of about 4% in people with schizophrenia, 
with most of these events occurring early in the course of the illness.
17
 
Healthcare systems in some high-income countries have invested in early 
intervention services designed to provide intensive multifaceted support 
for young people experiencing a first psychotic episode; these services 
can reduce suicide rates.
18
 More generally, they can reduce symptomatic 
relapse and improve vocational recovery and quality of life,
19
 and can 
substantially reduce short- and long-term health, social care and other 
service-related costs.
20
 
3.2.  Comorbidities 
Two major comorbidity ‘themes’ are becoming more widely 
appreciated in this area. One is the high risk of physical morbidity and 
premature mortality among people with enduring mental health 
problems, in part linked to the risks that follow from poor health 
behaviors. The other is the high rate of psychiatric morbidity in people 
with long-term physical health conditions such as cancer, coronary heart 
disease and diabetes. In both cases, the comorbidities might considerably 
impair health and quality of life – the overall impact often being greater 
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than the sum of the parts – which then complicates treatment and adds 
significantly to healthcare costs. 
Mental and physical health problems often cluster together in 
childhood, for instance, leading to higher service-related costs.
21,22
 
People with schizophrenia have above-average rates of physical 
morbidity (particularly cardiovascular disease and type 2 diabetes) and 
lower life expectancy: up to 20 years lower compared with the general 
population.
23
 Indeed, while public health programs have achieved 
successes in some high-profile areas over recent decades, the relative 
disadvantage experienced by people with severe mental health problems 
appears to have widened: a Swedish study found that while deaths from 
heart disease had decreased in the general population, they increased for 
people with schizophrenia.
24
 Tobacco use is especially high among 
people with psychosis
25
 and is above average for people with most 
mental illnesses,
26
 with obvious longer-term health consequences. 
Treatments might actually exacerbate the situation: some antipsychotic 
medications are known to cause rapid weight gain and metabolic 
complications.
27
  
Depression is frequently associated with poor physical health, with 
diabetes being very common for example, generating difficulties in terms 
of self-management of health and increasing the likelihood of 
absenteeism from work.
28
 A calculation for the US suggested that 
healthcare costs for individuals with severe depression and diabetes are 
almost twice those for people with diabetes alone.
29
 The broader 
economic consequences are also considerable.
30
 However, ‘collaborative 
care’ approaches delivered in primary care settings – antidepressant 
medications, perhaps psychological therapy, and usually with nurse-led 
case management – have been shown to improve health and to be cost-
effective.
31,32
  Comorbidity seems to be the rule rather than the exception, 
and the area of diabetes and depression is one of the few that has been 
researched and for which interventions have been developed. More 
attention is now being paid to innovative forms of liaison psychiatry, and 
the re-designing of payment mechanisms to encourage better integrated 
working across specialties. 
Naylor et al
33
 conservatively estimated that £1 in every £8 of 
healthcare expenditure in England on people with long-term (physical) 
 Mental Health 11 
conditions is linked to their (often untreated) poor mental health. The 
increase in total healthcare costs was at least 45% for each person with 
both a long-term condition and a comorbid mental health problem. This 
evidence review also pointed to complicated patterns of association with 
other factors: people with comorbid physical and mental health problems 
were more likely to be living in deprived areas and to have poorer access 
to economic, social and healthcare resources. Associations with 
inequalities were particularly marked. 
One more example can be offered: the interconnections between HIV 
and mental illness. Two evidence reviews highlight the prevalence of this 
comorbidity, and the scale of the challenge in Africa. Breuer et al
34
 show 
how complex this bi-directional interconnection can be, with reported 
prevalence rates of mental illness among people living with HIV or 
AIDS being as high as 19% in one study. Brandt
35
 concluded that ‘about 
half of HIV-infected adults sampled had some form of psychiatric 
disorder, with depression the most common individual problem,’ 
considerably higher than for equivalent people not infected with HIV.  
Antiretroviral treatment was associated with lower rates of psychiatric 
morbidity. A cohort study in Malawi found that HIV-infected women do 
not have higher rates of postpartum depression than uninfected women, 
but depression was higher among women with an HIV-infected child.
36
 
3.3.  Multiple Needs and Impacts 
Mental health problems that are unrecognized, poorly managed or 
unresponsive to treatment can have enduring and considerable impacts 
across many life domains. In turn, there could be needs for intervention 
from many service or policy sectors, such as social care, housing, 
employment, criminal justice, income support and other systems. 
Consequently, although the direct healthcare treatment costs will often be 
substantial – mental health needs account for more than 10% of total 
health budgets in many high-income countries, for example – the indirect 
costs can high too. 
We discuss employment-related impacts and criminal justice impacts 
in later sub-sections, but note here that both make substantial 
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contributions to overall costs for many people with mental health 
problems.  
Partly because of the employment difficulties that many individuals 
with mental health issues face – either in getting a job in the first place, 
or keeping it, or being able to work full-time – they would benefit from 
welfare advice, and many are reliant on social security (welfare) 
payments. Some are caught in a vicious downward spiral: their mental 
health problems damage their employment prospects and plunge them 
into poverty, the stress of which then exacerbates the underlying 
symptoms. The combined effects of severe and enduring mental illness 
and persistent poverty can lead to situations where individuals are 
socially isolated and not able to access appropriate services. Specialist 
advice around welfare entitlements, debt management and community 
resources can be cost-effective.
37,38 
Another substantial impact of mental health problems outside the 
healthcare sector is in the domain of housing. Social and economic 
disadvantage can generate housing problems. Homelessness is common 
for people with schizophrenia and other psychotic disorders.
39
 Again 
there is a vicious circle of mental health problems leading to economic 
disadvantage, leading in turn to an inability to keep up rental or mortgage 
payments, which causes more stress and symptomatic relapse. To take 
just one illustration, patients discharged from psychiatric inpatient 
settings may relapse if they are not able to move into sufficiently 
supportive community environments.
40
 Homelessness is itself socially 
costly, and providing supported housing is also going to need injection of 
resources from public or charitable sources. Supported housing programs 
can be effective in improving quality of life and health
41
 and cost-
effective in reducing use of emergency room and outpatient services.
41,42
 
These successful interventions involve well-coordinated actions across 
health, housing and other relevant sectors, including help with managing 
social security benefits and paying bills. 
Indeed, a common theme that emerges from much of the evaluative 
research on interventions in the mental health field is this need for 
coordinated action across sectors, systems and budgets. This helps to 
avoid gaps through which individuals with complex needs might fall, 
thereby reducing the occurrence of distressing and costly crises. But a 
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perennial challenge is ‘silo-budgeting’, where budget-holders are so 
focused on protecting their own resources and carefully managing their 
own spending that they shift costs and dump problems onto other 
budgets. Silo-budgeting is probably more likely in periods when 
resources are under particular pressure, such as during macroeconomic 
recession, and yet that is precisely the time when coordinated action is 
most needed. 
Taking a bird’s-eye view of these multiple needs and their 
consequences, we can see from a number of cost-of-illness and similar 
studies how non-healthcare costs can stack up relative to healthcare 
costs. Charrier et al,
43
 for example, reviewed evidence on the cost of 
schizophrenia in OECD countries, finding substantial productivity losses, 
high costs to unpaid family carers, and wide-ranging impacts on other 
service systems. High non-healthcare costs associated with schizophrenia 
have also been documented in countries such as Japan,
44
 China
45
 and 
Thailand.
46
 For bipolar disorder, a systematic review found many studies 
where the non-healthcare costs dominated health costs,
47
 and this pattern 
is even more marked when looking at depression
48
 and anxiety 
disorders.
49
 Indeed, one English study calculated that 90% of the societal 
cost of depression was due to unemployment and absenteeism from 
work.
50
 In childhood, there can be high-cost impacts in the education 
system: childhood mental health problems in Britain generated costs for 
frontline education services twelve times greater than costs for specialty 
mental health services.
51
  
Looking to the future, calculations by Bloom et al
52
 compared 
expected costs for mental health problems with those for the four non-
communicable diseases focused on by a United Nations High-Level 
Meeting in 2011. (To widespread surprise, the UN excluded mental 
illness from its list of non-communicable diseases.) Bloom found that 
total lost output from mental health problems over the following 20 years 
was (on an annual basis) equivalent to about 5% of global GDP in 2010. 
This impact was greater than that of cardiovascular diseases, and vastly 
greater than diabetes, chronic respiratory diseases and cancer. 
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3.4.  Impacts on Others 
There are numerous ‘spillover’ or ‘external’ effects of mental health 
problems on other people, both contemporaneously and over time. Three 
areas illustrate well these often wide-ranging impacts: maternal mental 
illness during the perinatal period, family impacts in schizophrenia, and 
consequences for health, time and quality of life for unpaid carers of 
people with dementia. There are also ways in which actions by external 
parties can have important benefits for people experiencing mental 
illness. 
Perinatal mental health problems can have deleterious consequences 
for the newly born children as they develop through childhood and 
adolescence (and also on the mother’s partner and other children). There 
are high risks that the child will have emotional, behavioral or 
intellectual problems,
53-56
 and also of intergenerational transmission of 
socio-economic disadvantage.
57
 Bauer et al
58
 examined the effects and 
associated costs of perinatal maternal depression on child development 
up to age 16 years from a London cohort study. The additional risks that 
children exposed to perinatal depression would develop emotional, 
behavioral or cognitive problems ranged from 5% to 21%, and there was 
a likelihood of 24% of having special educational needs. Discounting 
costs back to the time of birth, each child exposed to perinatal depression 
generated public sector costs of £3,030, reduced earnings of £1,400 and 
health-related quality of life losses valued at £3,760, after adjusting for 
other covariates. Interventions designed to recognize and treat mental 
health problems in women during pregnancy or soon after birth, which 
might already look encouraging in terms of their impacts on mothers and 
cost-effective,
59
 might therefore be further justified by reference to 
effects on their offspring. Thus far, however, these wider effects have not 
been included in evaluative studies. 
As with other mental illnesses, the distressing and disabling 
experiences of people with schizophrenia can have impacts on family 
members.
60 
If a psychotic episode leads to violence, which can 
sometimes happen (see section 3.6), then there could be wider external 
impacts. Families with a member with schizophrenia may incur direct or 
indirect costs themselves, such as out-of-pocket payments for services or 
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to transport the person with schizophrenia to treatment, or lost earnings if 
they give up employment or take time off work to provide support. These 
are largely hidden costs, but they are of importance if a mental health 
system is heavily reliant on the unpaid inputs of family and other carers. 
On the other hand, high levels of ‘expressed emotion’ within a family – 
high levels of criticism, hostility, emotional over-involvement and over-
exuberant praise – have been known to exacerbate psychotic symptoms. 
Family-focused therapy can be quite effective in some cases
61
 and also 
potentially cost-effective.
62 
In the dementia area, reliance on unpaid care inputs from spouses and 
family members is enormous across every country.
63
 Responsibility for 
caring can take its toll on the health and wellbeing of unpaid carers, with 
high rates of depression and anxiety, for example.
64
 With the right kinds 
of support, these ‘burdens’ can often be lessened, and in ways that are 
cost-effective. A sample of family carers of people with dementia in the 
UK were given information on where to get emotional support, and 
taught (personalized) techniques to improve their understanding and 
manage the behaviors of the person they cared for, change unhelpful 
thoughts, promote acceptance, improve communication, plan for the 
future, relax and engage in meaningful enjoyable activities. Compared to 
standard support arrangements, this intervention significantly improved 
carer health-related quality of life and mental health over a 24-month 
period, had no effects (negative or positive) on illness severity, 
neuropsychiatric symptoms or quality of life for the people with 
dementia, and was no more costly than.
65,66
 
3.5.  Employment 
The OECD compiled an excellent, wide-ranging report on the links 
between mental health and work.
67
 One of its central messages is that the 
links between mental illness and employment difficulties are many and 
complex. People with established disorders face greater risks of 
unemployment and job insecurity, higher rates of absenteeism and 
presenteeism, lower earnings, and a greater likelihood of early 
retirement.
68,69
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Another part of this complex set of interconnections is the modal age 
for incidence of psychotic illnesses (in late adolescence and early 
adulthood), which can seriously compromise individuals’ abilities to 
build human capital through education and training, and thereby damage 
their life-long economic potential. Indeed, across a range of psychiatric 
diagnoses, individuals with disorders have above-average propensities to 
leave education early.
67
 Employment is the main source of household 
income for most people, but also influences social status and roles, 
fosters social participation, and is a source of self-concept. Long-term 
employment difficulties increase the risk of unmanageable personal debt 
and poverty, in turn further worsening mental health.
70
 For the wider 
society, employment affects community prosperity and national 
economic growth.  
The links between mental illness and employment become especially 
difficult when an economy is under pressure. A study that looked at the 
27 European Union countries demonstrated that people with mental 
health problems found it harder to get employment during the global 
macroeconomic recession of recent years than people without such 
morbidity. Moreover, the relative disadvantage was significantly greater 
in countries which displayed higher levels of stigmatizing attitudes 
towards mental illness.
71 
One response to the danger of a damaging, costly downward spiral 
linking poor mental health and poor employment experiences and 
outcomes has been to try to create better employment opportunities for 
people with a history of mental illness, breaking down discriminatory 
and attitudinal barriers. There is evidence from many countries that 
supported employment approaches – intensive skilled support both for 
employees with mental disorders and their employers in ‘open 
employment’ settings – are more effective and cost-effective than 
traditional approaches centered around ‘sheltered workshops’. The best 
known is Individual Placement and Support (IPS) which helps 
individuals obtain competitive employment as quickly as possible and 
then provides on-the-job training and support from employment 
specialists who are usually integrated into clinical teams, with welfare 
benefits counselling provided through the transition phase into 
employment. When implemented properly, IPS is cost-effective 
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compared to traditional vocational support approaches.
72
 The six-country 
EQOLISE study conducted in Europe, for instance, found both lower 
costs and better employment outcomes for IPS.
73 
There are characteristics of workplaces that can cause mental health 
problems to emerge or worsen, such as stress and bullying. 
Consequently, another response to the employment challenge has been 
legislation that clarifies and protects rights to employment and to 
encourage mental disorders to be viewed in the same way as other 
conditions and disabilities. Most people with mental health problems 
want to work and can do so when well, deriving therapeutic as well as 
economic benefits from it, but can become disillusioned and disengaged 
if their aspirations are repeatedly dashed. 
From the perspective of the employer, there are two big issues. One is 
that someone with a history of mental illness may be perceived to be less 
productive than someone without such a background. Many individuals 
therefore choose not to disclose their health histories when seeking 
employment.
74
 Productivity losses that could result if a key employee 
takes time off work for short or long periods could be tackled by taking 
appropriate preventive or ameliorative action in the workplace. While not 
all risk factors for mental disorders are within an employer’s control, 
some of them undoubtedly are, such as the demands made on employees, 
the opportunities for them to participate in decision-making, prospects 
for promotion, workplace harassment, and bullying.  
Workplace well-being programs and screening for stress can be 
highly cost-effective, both for the employer and the broader 
society.
75,76,38
 Among the measures that employers can take to make it 
easier for individuals with a history of, or currently experiencing mental 
health problems to remain in work and to remain productive are 
adjustments to the workplace, such as flexible scheduling or quieter or 
less stressful working environments, allowing people to work from 
home, and training managers in better mental health awareness, whilst 
also helping employees to build up resilience. A number of these 
workplace-based interventions have been shown to be cost-effective.
77 
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3.6.  Antisocial Behavior and Crime 
There is a widely held view that people who experience or have a 
history of mental illness are unpredictable and perhaps violent, a view 
reinforced by inaccurate and irresponsible reporting in some parts of the 
media. Thornicroft et al
78
 analyzed newspaper reporting of mental health 
topics by British newspapers, finding that 14% made explicit reference to 
people with mental health problems being a danger to others and/or using 
stigmatizing language. 
Although the risks are often exaggerated, it is nevertheless correct 
that some mental illnesses are associated with a greater likelihood of 
antisocial behavior or crime. We have already alluded to findings that 
many children with conduct disorder or displaying antisocial behavior 
will often – without adequate treatment – become adolescent delinquents 
and adult criminals.
79
 Substance abuse can trigger acquisitive crime, with 
high costs for the criminal justice system and victims.
80
 It is also known 
that, for example, 5% of serious violent crime in England and Wales is 
committed by individuals under the care of specialist mental health 
services,
81
 and that a disproportionate number of homicides in Australia 
are committed by people experiencing their first florid symptoms of 
psychosis.
82
 A study in the USA found that the risk of violence was 
highest among individuals with alcohol disorders (25%) and drug 
disorders (35%), much more than the risk among people with 
schizophrenia (13%).
83
 Not surprisingly, risks are higher for those 
individuals who are not adhering to their treatment plans.
84
 Again, the 
economic consequences can be large. 
Societal responses to these patterns can be both inappropriate and 
appropriate: stigmatizing and punishing, or constructively responding to 
needs by offering evidence-based treatment and support. 
Epidemiological surveys have shown that high proportions of people in 
prison have previously unrecognized and therefore untreated mental 
disorders.
85
 Poor access to mental health services can propel people in 
the wrong direction: one US study found that when inpatient psychiatric 
beds availability fell, there was an increase in the risk of imprisonment 
for minor charges among people with severe mental health problems, 
linked particularly to substance abuse.
86
 Legal powers of compulsory 
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treatment exist in most countries, which may be good so long as they are 
not abused. The systematic murder of huge numbers of mentally ill 
people by the authoritarian regimes of Hitler’s Germany and Stalin’s 
Russia may be at the extreme end of the abuse spectrum, but there are 
myriad other examples of mistreatment and denial of basic rights across 
the whole world.
87
 
More appropriate responses include a range of criminal justice liaison 
and diversion services which identify people with mental health 
problems who come into contact with criminal justice agencies such as 
police or courts, and then direct them towards more appropriate mental 
health services. There are suggestions of effectiveness,
88
 but as yet little 
economic evidence.  
It needs to be emphasized that people with a history of mental health 
problems have an above-average risk of being the victims of crime. The 
risk of being a victim of violence in the previous 12 months is three to 
ten times greater for people with severe mental illness compared to the 
general population.
89
 Analyses of national data for Sweden showed that 
people with mental health problems were five times more likely to be the 
victim of homicide than people without such problems.
90
 Experiencing 
violence is never good, but the consequences can be magnified for 
people with pre-existing mental illness. Indeed, people who experience 
violence – whether in childhood or adulthood – are more likely to 
develop mental health problems later in life.
91 
Although there are policy and practice issues to be addressed, each 
with an economic dimension, the key message is this, as summarized by 
Howard et al in a recent evidence summary: ‘Most people with mental 
illness are not violent, and most people who are violent are not mentally 
ill’.92 
3.7.  Suicide and Self-harm 
Self-harm, suicide attempts and successful suicides are all relatively 
rare but obviously very disturbing events. They are closely linked to 
mental health problems. They are also strongly associated with 
socioeconomic deprivation, and with the state of the economy. Many 
studies have now shown that macroeconomic recession – through its 
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effects on unemployment levels and duration, job insecurity, earnings, 
unsecured debt and so on – is associated with higher suicide rates. Chang 
et al
93
 examined data for 54 European and American countries, finding 
that suicide rates increased significantly after the 2008 global economic 
crisis, more so for men than women, and more noticeably in countries 
where the recession was deeper (as measured by job losses). In South 
Korea, income-related inequalities in depression and suicidal behavior 
widened enormously over a 10-year period following an earlier 
economic crisis: poorer groups fared much less well.
94
  
Suicide has many distressing impacts. One less distressing but still 
pertinent impact is the economic cost, including intangible costs such as 
the value of lost life, lost productivity (both waged and unwaged), police 
time and funerals. The cost of a completed suicide for someone of 
working age in the UK has been estimated to exceed £1.6 million, for 
example.
95
 Self-harm and non-fatal suicide attempts can also be costly in 
terms of emergency and other healthcare, including longer-term 
psychiatric treatment.
96 
Better identification of people at risk of suicide and better responses 
to self-harm have been shown to be effective, and there is emerging 
evidence of cost-effectiveness for interventions such as manual-assisted 
cognitive behavior therapy (CBT) for adults with a history of recurrent 
deliberate self-harm,
97
 and suicide-awareness training for GPs and other 
health professionals, followed by CBT
38
. 
3.8.  Stigma and Discrimination 
The stigma experienced by many people with schizophrenia and 
psychosis can affect many aspects of their lives, limiting access to 
employment and housing, harming social relationships, reducing self-
esteem and reducing the likelihood that they seek treatment.
98,99
 Through 
its impacts on ‘employment, income, public views about resource 
allocation and healthcare costs’ it can also impose sizeable costs.100  
Evans-Lacko et al
101
 systematically mapped European evidence on 
stigma and social exclusion experienced by people with mental health 
problems. Although the body of evidence is modest compared to, say, 
work on clinical trials of interventions, there is now some wide-ranging 
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and high-quality evidence that documents the stigma, discrimination and 
social exclusion that is so often experienced. But evidence is sadly 
lacking on interventions that can reduce stigma and promote social 
inclusion, and there is also a paucity of evidence on interventions that 
promote resilience or protect against stigma over the life-course. Social 
marketing campaigns have been suggested ‘as a way to reach the public, 
to modify health or pro-social behaviors and to promote specific health 
issues’.102 These approaches are potentially highly cost-effective.103,104 
3.9.  Poverty and Inequalities 
Economic ‘difficulties’ experienced by individuals – such as 
unemployment, low income, unsecured debt, housing uncertainty and 
social deprivation – have all been linked with incidence or exacerbation 
of health problems, including mental illness and, as we noted earlier, 
suicide.
105
 Again as noted above, there is often a vicious circle at work, 
since having a mental health problem puts an individual at greater risk of 
employment difficulties, rent arrears, other debt, and poverty.
106,107
 
This has generated two hypotheses about the underlying associations. 
The social causation hypothesis argues that economic disadvantage such 
as poverty increases the risk of mental illness by augmenting risk factors 
– such as financial stress, stigma, social exclusion, and malnutrition – 
and decreasing protective factors such as education and social capital. 
Mental health problems may worsen if someone is unable to access good 
treatment. The social selection or ‘drift’ hypothesis argues that people 
with mental health problems face higher risks of remaining or falling into 
poverty because of the costs of their treatment (if they have to pay 
themselves), lost or disrupted employment, lower productivity when at 
work, and hence reduced earnings. The former explanation may be more 
relevant for disorders such as depression and anxiety, while the latter 
might be more relevant for severe mental disorders such as 
schizophrenia. 
The strong but often complex links between poverty and mental 
disorder support the case for targeted anti-poverty programs to break into 
the cycle, such as provision of effective treatment and support services 
that are accessible to all, resilience-building efforts, investment in 
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education and housing, cash transfer and asset-promotion programs, and 
enforcement of human rights protection.
107,108 
A related question is the impact of inequalities. There are wide and 
deep-rooted inequalities in incidence and prevalence in relation to mental 
health needs. Income-related inequalities in mental health are much 
greater than in physical health.
109
 But there are also wide inequalities in 
access to treatments (and hence to the therapeutic benefits they generate) 
even in countries like the UK with tax-funded, universal healthcare 
provision.
110
 Those inequalities are not only income-related but also 
linked to race, ethnicity, gender, age, language, religion, and place of 
residence.
111
 
4.   Financing and Expenditure 
4.1.  Expenditure 
 Global expenditure on mental health has been estimated to average 
1.63 US$ per person per year.
112
 This is the median amount, around 
which there is enormous variation: expenditure per capita is more than 
200 times higher in high-income countries (US$44.84) than in LAMICs 
(averaging US$0.20 in low-income, US$0.59 in low-middle-income and 
US$3.76 in upper-middle-income countries). This wide difference is only 
partly accounted for by the income level: there are also inter-country 
differences in total health budgets and the priority attached to mental 
health within them.
113
 The percentage of the health budget allocated to 
mental health averages 2.8% (median) across all WHO countries for 
which data are available. LAMICs spend lower percentages of the health 
budget on mental health: the averages are 0.53% in low-income 
countries, and 5.10% averaged across high-income countries.  
 These expenditures look especially low when compared with the 
contribution of mental disorders to global burden of disease,
114
 and help 
to explain the wide gap between prevalence and treatment (see section 
2.2 above). There is also the problem that quite high proportions of 
expenditure committed to mental health are tied up in mental hospitals in 
LAMICs (73%, compared to 54% in high-income countries).
112
 Those 
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hospitals can provide treatment only to a small number of people and 
often what is provided is of dubious quality
115
 
 Underinvestment in mental health will have unfavorable 
consequences not only for the mental health and wellbeing of people 
with or at risk of developing these disorders, but also for economic 
development.
107
 A study for the World Economic Forum estimated the 
global cost of mental health problems to be US$ 2.5 trillion in 2010 
(64% of it occurring in high-income countries), projected to rise to US$ 
6.0 trillion by 2030.
116
 Two-thirds of the total was accounted for by 
indirect costs. In the same study, the cumulative global impact of mental 
disorders in terms of lost economic output was projected to be US$ 16.3 
trillion over the next 20 years (with just over half this amount in high-
income countries), estimated to be equivalent to more than 1% of 
GDP.
117
 When compared with other non-communicable diseases, mental 
ill-health ranked alongside cardiovascular disease in terms of its impact 
on lost economic output, and was substantially greater than cancer, 
chronic respiratory diseases, and diabetes. 
4.2.  Financing 
 Financing health care services is complex, with strategic decision-
makers – at national, regional or local levels – having to trade-off 
affordability, targeting, access, equity and efficiency. For most 
individuals, their risk of needing health care is highly uncertain, but 
when they are ill, treatment costs and losses in earnings can be huge. 
This is why all high-income countries rely heavily on pre-payment 
financing arrangements - through taxation, social health insurance or 
private voluntary health insurance – in order to pool risks and generally 
redistribute the benefits of health care towards individuals with greater 
health needs. If pre-payment arrangements are progressive (with poorer 
individuals paying lower amounts for equivalent health care), then they 
are also redistributive in this sense too. Both types of redistribution are 
important in view of the potentially enormous lifetime costs of mental 
health treatment and the low socioeconomic status of many people with 
enduring mental health problems.  
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 The chapter in this volume by Preker et al
118
 comprehensively covers 
the principles of healthcare financing; here we briefly discuss the main 
advantages and disadvantages of different financing mechanisms 
specifically in relation to mental health care. 
 Taxation-based financing. Taxes can be levied by one or more 
different tiers of government; some tax revenues might be hypothecated 
for specific purposes such as health. Taxation-based financing tends to 
be progressive, with contributions mandatory and linked to income, thus 
taking an individual’s ability to pay into account. It usually offers 
universal coverage, which is especially important given that mental 
illness can leave people socially marginalized and economically 
disadvantaged: other financing methods may exclude people from 
coverage if they are not employed or cannot afford insurance premiums 
(see below). Means-testing can further support redistributive goals, but 
co-payments may be barriers to utilization for people who are already 
perhaps reluctant service users, and can therefore undermine pursuit of 
equity goals.  
 Although tax-based financing is mainly associated with high-income 
countries, it is used to resource mental health care in some LAMICs (e.g. 
Azerbaijan, Kenya, Kyrgyz, Zambia),
119
 although these countries may 
also have high levels of out-of-pocket financing such as user charges and 
co-payments. Health care funding may fluctuate with the state of the 
national economy: many countries hit hardest by the recent global 
economic recession were further hit by governmental austerity 
measures.
120
 In low-income countries, government may not be able to 
raise sufficient tax revenues to pay for a decent health care system, and – 
as we have seen – mental health may be a low priority compared to other 
health needs.
121
 People with mental health problems may find that, 
although they are covered in principle, access is limited and quality is 
poor. Unhypothecated taxes have been criticized for not being 
transparent, public sector bureaucracy may be seen as a source of 
inefficiency, politicians might be seen to be using health care for political 
purposes, and patients may feel that a tax-based system offers them 
limited choice.  
 The efficiency and equity implications of a tax-based system depend 
somewhat on how funds are allocated from the central collecting body 
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(such as the finance or health ministry) to population subgroups, 
localities or facilities. In England, fairly sophisticated resource allocation 
formulae use weightings to capture variations in need linked to age, 
gender, ethnicity and indicators of disadvantage. But such an approach is 
quite data-heavy, and less sophisticated systems may allocate on the 
basis of historical expenditure patterns, which is unlikely to be efficient 
or fair, nor will it incentivize innovation or better responsiveness.  
 Social health insurance. The main alternative to taxation in high-
income countries is social health insurance (SHI). It is the dominant 
financing mechanism in much of Western Europe (e.g. in Czech 
Republic, France, Germany, Netherlands, Romania), with revenue 
collected by quasi-public bodies (‘sickness funds’). SHI is also 
increasingly common in Asia (e.g. China, Japan, Korea, Malaysia 
Taiwan), South America (although coverage there tends to be confined to 
urban areas), and many east European and former Soviet Union states 
(although other financing mechanisms are also used).
119
 
 SHI systems differ from country to country, but share some common 
features: contributions are usually compulsory for all or most of the 
population, and they are linked to salaries, with employers typically 
making contributions. People at high risk of mental health problems do 
not face higher premiums as they would under private voluntary 
insurance (see below), although if not in employment they may find 
themselves excluded. If there is no risk-rating, risk-adjustment 
mechanisms are often used so that no one sickness fund is unduly 
disadvantaged by the ‘risk profile’ of the people it covers. Eligibility for 
benefits is usually standardized for all enrollees. Transfers are often 
made from general taxation to sickness funds to provide cover for 
unemployed, retired and other disadvantaged or vulnerable people. In 
most low-income countries, only those individuals in formal employment 
tend to be eligible, indeed some SHI schemes are confined to public 
sector employees in urban areas. This is problematic given that more 
severe and enduring mental health problems are associated with low 
employment rates and low income, with the causal connections working 
in both directions, as we described in section 3.5. Another concern is that 
an emerging SHI system in a low-income country could divert resources 
away from poorer regions or individuals. A more general issue is moral 
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hazard, shared with tax-based financing, when there is no charge at the 
point of utilization, because individuals may be tempted to over-use 
health services. 
 Private (voluntary) health insurance. Private health insurance (or 
voluntary insurance, as it is sometimes described) shares advantages with 
tax-based and SHI in that it pools risks across individuals, and allows 
those individuals to smooth their expected consumption.
118
 A major 
disadvantage of private insurance is that, because it is often risk-rated 
(offering lower premiums to lower-risk individuals) and not mandatory, 
it may not be affordable for people with mental health problems (leaving 
them uninsured), and can lead to adverse selection, and ‘cream-
skimming’. In other words, low-risk individuals move out of a scheme if 
asked to pay more than they consider reasonable, and if they feel they are 
cross-subsidizing high-risk individuals (such as those with enduring 
mental health problems). Meanwhile, insurers may try to encourage low-
risk individuals by charging lower premiums and using high charges or 
other means to exclude other groups, again including those with mental 
health problems. If an insurance plan exempts existing conditions from 
the benefit packages – which is common – then individuals with a family 
history of mental health problems or suspected genetic predisposition to 
mental illness (such as schizophrenia or early-onset dementia) could find 
premiums to be prohibitively expensive or simply unavailable. As our 
understanding and use of gene profiling develops, this could become a 
bigger and bigger issue.  
 Private health insurance may be the only financing mechanism 
available to large parts of the population other than out-of-pocket 
payments (as historically in the US, with mental health cover being very 
limited).
122
 The failure of this type of financing to provide adequate 
cover for people with mental health problems led to the Mental Health 
Parity and Addiction Equity Act (MHPAEA) and the Patient Protection 
and Affordable Care Act (ACA), both in 2008, which extended health 
insurance cover to more people and expanded its scope to include mental 
health and substance abuse benefits.
123
 Private health insurance may 
fulfill other roles: as a substitute for SHI (e.g. in Germany for higher paid 
workers), as a complement to public entitlement (e.g. in France to cover 
co-payments within the public health system, or in Chile where it is 
 Mental Health 27 
purchased by higher-income groups) or as a supplement (e.g. in Ireland 
to reduce waiting times and improve choice).
124
 
 Evidence from many countries clearly shows that private health 
insurance is inefficient and inequitable when looked at from the 
perspective of people with mental health needs.
119,125,126
 It may take 
heavy regulation, generous subsidies or a tax-based or SHI-based safety 
net to begin to counter some of these disadvantages.
123,127
 Nevertheless, 
private health insurance has been advocated by the WHO
128
 as better 
than what might be the only alternative in many LAMICs, which is out-
of-pocket payments. There has also been growth in use of private 
insurance to pay for specialist treatment (e.g. for addictions), or by 
employers to treat work-related stress.  
 Out-of-pocket payments. Individuals using services may face user 
charges or co-payments, one aim being to discourage excessive or 
inappropriate utilization (where the marginal opportunity cost of delivery 
exceeds what is seen as the marginal social benefit of treatment). In some 
contexts, out-of-pocket payments may be considered to be the only 
feasible way to generate revenue for a mental health system because of a 
weak tax base, low rates of formal employment, or the very low priority 
given to mental illness (as in Nepal and Pakistan).
119
 Indeed, out-of-
pocket payments account for significant proportions of total expenditure 
on mental health care in most low-income countries, although they tend 
not to be the dominant financing mechanism. 
 However, such out-of-pocket payments may deter people from 
accessing treatment when they need it, with the consequence in some 
cases that symptoms worsen to the point where expensive, crisis-driven 
care is needed.
129
 The adverse effects of such deterrence are likely to be 
especially acute in relation to mental health problems, where individuals 
might already be reluctant to seek treatment because of stigma, fear, 
impaired cognition, or lack of insight into the state of their health. The 
efficiency and distributional implications could be dire, especially as 
many of those in need of mental health treatment will be the least able to 
pay.
126,130
 Allowing such individuals to be exempt from charges might be 
one way to address this problem,
131
 but this will add further bureaucracy 
to what is often already quite a costly system to administer. 
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 International aid. In high-income countries, pre-payment 
arrangements (various combinations of taxation, social health insurance 
and private health insurance) dominate both health care financing in 
general, and mental health financing in particular. However, in most low-
income countries, mental health care is still most likely to be funded 
directly by users or families through out-of-pocket payments. Even 
though international non-governmental organizations (NGO) and foreign 
governments might provide sometimes substantial support for health 
systems, international aid of this kind very often excludes mental health 
care. It is also highly variable and unstable as a platform for long-term 
planning. 
5.   Economic Evaluation for Better Mental Health Policies 
and Treatment 
We have already alluded to economic evaluative evidence in the previous 
section when discussing the main challenges associated with mental 
health problems. Here we briefly explain what these evaluations look 
like, and then discuss some methodological issues that can arise in 
mental health contexts. 
5.1.  Evaluation Questions 
The central clinical or effectiveness question when evaluating an 
intervention (such as a service, medication, preventive strategy or wider 
policy initiative) is whether it reduces or removes symptoms or improves 
quality of life. The economic question is then whether the resources 
needed to deliver the intervention are justified by the outcomes achieved. 
There are different ‘types’ of economic evaluation, sharing many 
common features, but differing in how they define and measure 
outcomes, because they seek to address slightly different questions. 
When evaluating an intervention targeted on a particular patient group in 
comparison to another intervention for the same disorder (such as two 
antidepressant medications), the most relevant outcomes will be specific 
to the diagnosis (alleviation of depressive symptoms) as well as some 
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more general indicators (such as quality of life and personal functioning). 
In this case, a cost-effectiveness analysis would be most appropriate, and 
this is the most commonly conducted type of health economic 
evaluation. A cost-effectiveness analysis tells decision-makers what 
course of action (i.e. what treatment) best meets clinical needs given 
available resources.
132
 
Some decisions in health and other systems raise broader questions; 
for example, should available resources be used to provide treatment for 
more people with depression or more people with schizophrenia or 
coronary heart disease? In this case, measuring depressive symptoms will 
not be enough, because patients with schizophrenia or coronary heart 
disease may have not have these symptoms, and even if they do, there 
are other treatment aims to take into account, such as reducing psychotic 
symptoms or reducing the risk of coronary events. An evaluation would 
therefore need a common measure of outcome that would allow the 
decision-maker to make comparisons across these different clinical 
fields. Economists have developed a generic outcome measure (‘utility’), 
often operationalized in terms of quality-adjusted life years (QALYs), 
which we describe further below. Another generic measure, used mainly 
in LAMIC studies, is the disability-adjusted life year (DALY). This form 
of economic evaluation is often called a cost-utility analysis: it tells the 
(strategic) decision-maker where they are likely to get the biggest impact 
from their resources by deploying them across a range of clinical areas. 
An even broader type of economic evaluation is a cost-benefit 
analysis. It is suitable if a decision-maker needs to choose how to 
allocate resources across quite diverse areas, such as healthcare, 
education or housing. The only currently feasible generic outcome 
measure in these circumstances is a monetary valuation of what is 
achieved. Cost-benefit analyses are not easy to undertake in mental 
health contexts, as it is difficult to calculate the societal value of the 
health and other outcomes of interventions. 
5.2.  Measuring Costs and Outcomes 
We have already seen that the cost impacts of many mental health 
problems can range broadly over many services and systems. They can 
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also extend over many years. We have also noted the multidimensional 
implications of poor mental health, which implies that the evaluation of 
the effectiveness of an intervention should aim to assess what happens in 
each of those various domains. The breadth of cost and outcome 
measurement is driven by what health economists call the perspective of 
the study: is the evaluation intended to help resource allocation within a 
particular agency (e.g. a community mental health service), or a 
particular system (e.g. the healthcare system), or a particular sector (e.g. 
government), or the whole society? The breadth of perspective will 
determine the breadth of both cost measurement and, to some extent, the 
choice of effectiveness or outcome measures.  
Costs can be direct and indirect. Direct costs include those associated 
with treatment of a disorder (e.g. amounts spent on medications and 
therapy sessions). Indirect costs include the value of lost productivity 
because of poor mental health, or the (imputed) cost of unpaid care 
provided by family members. In the mental health field, as we have seen, 
the indirect costs can often overshadowing direct healthcare costs. 
On the outcome side of an economic evaluation, the approach in 
mental health contexts is the same as in other areas of health, with the 
most relevant measures when considering treatments for a given disorder 
being those that assess changes in symptoms, behavior, functioning, and 
attitudes, and quality of life. QALYs (utilities) or other generic 
dimensions can also be added as measures to inform more strategic 
decision-making such as when setting departmental budgets within a 
hospital, or taking strategic decisions about which needs to prioritize 
within a national healthcare system. There has been debate as to whether 
QALYs can be measured well enough for some mental health diagnoses 
(see below), but almost every health economic evaluation today – in 
Europe at least – would include a QALY measure, alongside symptom or 
similar ‘clinical’ measures. The most widely used QALY-generating tool 
is the EQ-5D.
133 
Both costs and outcomes would ideally be measured over a period of 
some years, given the chronicity of most mental illnesses and the 
potential for long-term gains from the most effective interventions. 
However, as with any evaluation, it often proves infeasible or too 
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expensive – or perhaps even ethically inadvisable – to continue to collect 
data over long periods from the same individuals. 
5.3.  Making Trade-offs 
The most difficult challenge in interpreting and using findings from an 
economic evaluation arises when one intervention is found to be more 
effective than another but also has higher costs. Which of the two 
interventions would then be seen to represent the best use of scarce 
resources? There is no simple answer: it depends what value the 
decision-maker attaches to the greater effectiveness, i.e. on the trade-off 
better outcomes and lower costs. This boils down to a value judgement.   
Health economic evaluations usually illustrate this trade-off by 
calculating the incremental cost-effectiveness ratio (ICER), defined as 
the extra cost associated with a new intervention divided by its additional 
effectiveness. For example, a study of computerized cognitive behavioral 
therapy (CCBT) for people with depression or anxiety found it to be 
better in alleviating symptoms and improving work and social 
functioning compared to treatment as usual,
134
 but it was also found to be 
more expensive to the health service.
135
 The cost of achieving an 
incremental improvement in depressive symptoms (measured by the 
Beck Depression Inventory) was found to be £21, equivalent to a cost of 
£2.50 per depression-free day over the study period. The decision-maker 
must then take a view as to whether this additional cost is worth paying. 
In this same study of CCBT the cost per QALY was £2190. This 
ICER value is potentially informative because there is a government-
funded (but independently managed) body in England and Wales – the 
National Institute for Health and Care Excellence (NICE) – that was 
established to help decision-makers in the tax-funded National Health 
Service (NHS) to weigh up the trade-offs. NICE produces clinical, public 
health and social care guidelines built on as much evidence as they can 
find, synthesized into effectiveness and cost-effectiveness conclusions. 
In helping providers and purchasers to decide whether better outcomes 
from a particular treatment are ‘worth’ the higher costs that may be 
needed to achieve them, they aim to calculate the cost per QALY and 
compare it with a (widely discussed) threshold value for cost-
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effectiveness. Currently, a treatment or other intervention that costs more 
than £30,000 per QALY would generally not be considered ‘worth it’.136 
This is because – according to the approach adopted by NICE on behalf 
of the NHS – the resources (represented by cost) could be better spent 
elsewhere in the healthcare system (i.e. on a different treatment, not 
necessarily for the same illness). The NICE threshold provides guidance 
rather than a rigid decision-making rule, with the intention of reminding 
everyone (clinical professionals, purchasers, patients, taxpayers and 
politicians) that resources are scarce, so that choices have to made about 
how they should be used.
137
 Some other countries have similar processes 
to guide allocation decisions.
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5.4.  Uses of Economic Evaluative Evidence 
Results from economic evaluations have many potential uses. 
Decision-makers in health and related systems across the world are 
increasingly turning to economics for evidence to inform, shape and 
support their decisions. More generally, there are many ways in which 
economic evaluation and other evidence is used. We offer some brief 
examples here to illustrate how information on costs and cost-
effectiveness evidence is being used.  
‘Cost-of-illness’ studies that add up the direct and indirect costs of a 
particular mental health problem give lobbyists and advocacy groups 
some economic ammunition to argue the case for more attention and 
resources to improve prevention, treatment and support. Pharmaceutical, 
medical devices and other companies might also use similar data to draw 
attention to what they would argue is a neglected or under-resourced area 
in order to provide a platform for marketing their wares. Those 
manufacturers might also invest in cost-effectiveness studies to support 
the case for their products. Indeed, in some countries there may be 
formal requirements for them to submit information on cost-effectiveness 
to regulatory or related bodies. Economic evidence can therefore also be 
used to help shape the local commissioning of treatments. 
Economic evidence is increasingly being used in the formulation and 
monitoring of policy by public bodies. For example, the Department of 
Health in England commissioned a study to examine the economic case 
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for mental health promotion and mental illness prevention.
38
 Similarly, 
the World Health Organization (WHO) has invested in cost-effectiveness 
evidence within its Choosing Interventions that are Cost Effective 
program, collating information for each of the 17 WHO sub-regions on 
the costs, impact on population health and cost-effectiveness of different 
health interventions.
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Some high-income countries have health technology appraisal (HTA) 
mechanisms to formally examine the cost-effectiveness of technologies 
to inform reimbursement and coverage decisions or develop treatment 
guidelines. NICE in England and Wales is one such body. In evaluating 
specific technologies and preparing guidelines for clinical practice, NICE 
makes copious use of economic evidence.  
However, even when there is an economic evidence base, it does not 
necessarily change policy or practice. There could be a number of 
barriers in the way.
115
 One of the most challenging is resource 
insufficiency: there are not enough funds to invest in interventions found 
to be most cost-effective, perhaps because – even though they are 
effective – they require a net increase in spending. Another barrier could 
be that available services are poorly distributed, available at the wrong 
place or time relative to needs, such as the tendency for specialist 
psychiatric services to be concentrated in large cities in many LAMICs. 
Or available services may be inappropriate, not matching what is needed 
or what would be chosen by individuals; for example, resources could 
have been sunk in large institutions, whereas best practice would be seen 
to be community-based. Silo-budgeting is another implementation 
barrier. 
5.5.  Evaluative Challenges 
Making an economic case for an intervention does not mean cutting 
costs but using resources (not just in the healthcare system, but across the 
whole economy) to their best effect: that is, ensuring that resources are 
used so as to achieve the greatest gains in health and quality of life. 
The pervasive characteristics of mental health problems and their 
consequences discussed in Section 3 have knock-on implications for the 
design, conduct, interpretation and utilization of cost-effectiveness and 
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other evaluative evidence. One immediate implication stems from the 
fact that most mental disorders, although primarily defined as ‘health 
problems’, have spillover effects in other domains of life, and therefore 
other domains of public policy. The costs of responding to the needs of 
children with emotional and behavioral problems, for example, tend to be 
higher in the education sector than in the health sector. The long-term 
costs of not adequately responding to childhood behavioral problems are 
much higher in the criminal justice system than in the health system. The 
major economic impact of depression is lost productivity because of 
disrupted employment, rather than treatment or crisis-response costs 
from healthcare interventions.  
Moreover, many of those spillover impacts are hidden from view. 
Lost productivity arising through unemployment or absenteeism may be 
visible and relatively straightforward to measure, but lost productivity 
through presenteeism is inherently difficult to quantify. Similarly, unpaid 
support provided by family members or others to someone with a mental 
illness is almost by its very nature something that is hidden from view, 
and yet the responsibilities that go with such support can damage a 
carer’s own health, wellbeing and economic position. Economic 
evaluations therefore need to be at least cognizant of these wider 
impacts, and better still to include them as measured elements of a study.  
We have also emphasized throughout the chapter that most mental 
health problems are chronic, and whilst effective treatment may alleviate 
the symptoms, the underlying condition rarely goes away. Indeed, for 
some people with particularly complicated circumstances or challenging 
symptoms, there may be no effective treatment. Interventions are usually 
judged – if only for pragmatic reasons – by their relatively short-term 
impacts, whether in terms of effectiveness or cost-effectiveness, whereas 
the true measure of impact ought generally to be assessed over a much 
longer period.  
A related challenge is what could be called ‘diagonal accounting’, 
where the costs of an intervention need to be compared with impacts 
(economic or otherwise) that are not only in another sector but in another 
time period. When budgets are tight, it can be hard to persuade decision-
makers to spend more, especially if the pay-offs will not be seen 
immediately and will not even benefit their own service or sector. 
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Some of the savings from an intervention – whether diagonal, vertical 
or horizontal – may not anyway be cashable. For example, an 
intervention that reduces hospital admissions but does not (either 
immediately or perhaps ever) close inpatient beds might not generate any 
savings at all. Similarly, reducing the time burden on unpaid family 
carers does not generally release any resources that are transferable to 
other uses. 
Many people with mental health needs also have other needs. The 
complex interplay between physical and mental health conditions can 
make evaluation quite challenging. A linked challenge is the problem of 
sample attrition in research, usually much higher in mental health studies 
than in other health economic evaluations. This attrition problem can 
arise partly because of comorbidities, partly because of the fluctuating 
nature of some mental illnesses which leave people unable to continue in 
a study or to participate at certain time-points, and partly because some 
people live chaotic lives as a result of their illness.  
We have mentioned earlier the insights gained by using QALY 
measures in economic evaluations, linked to the difficult task facing 
some strategic decision-makers of making comparisons and allocating 
resources across disease areas or medical specialties. In Europe and 
many other regions of the world, almost every health economic 
evaluation includes a QALY (or DALY) measure nowadays, usually 
alongside symptom and similar ‘clinical’ outcome measures. But the 
most widely used QALY-generating tools, such as the EQ-5D, do not 
always perform well (from a psychometric standpoint) in studies of 
people with severe mental health problems, or for the youngest or oldest 
patients.
140
 Specific QALY measures have therefore been developed for 
some conditions, such as dementia.
141
  
Benefit measurement – in the evaluative sense of converting 
outcomes to monetary magnitudes – is even more challenging. It is 
intrinsically difficult to convert an indicator of symptom or quality of life 
improvement into a monetary value. In those rare cases where the 
primary outcome is something such as productivity improvement – as 
with evaluations of supported employment schemes – it is potentially 
possible to convert the effectiveness scores into something that can be 
directly compared with costs.
73
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6.   Public Policy Challenges 
Some mental health problems are preventable or the risks of their 
occurrence can be reduced, such as those stemming from traumatic 
experience, non- or misdiagnosis. An important public policy theme 
should therefore be to do better at preventing problems from emerging, 
but when they do emerge, to identify and treat them early. Moreover, as 
we have emphasized time and again in this chapter, some of these actions 
– preventive and ameliorative – are needed outside the health sector as 
conventionally defined.  
Relatedly, therefore, early intervention should be, and commonly is, a 
core policy theme, with good evidence from a number of different 
diagnostic areas of the effectiveness and cost-effectiveness of early 
actions to detect and respond to individual needs and preferences.  
Suicide is an especially distressing consequence of poor mental 
health, even if it is relatively rare. Suicide prevention features quite 
prominently as an objective of many national mental health plans, and 
has acquired greater urgency in recent years with the realization that 
economic recession and macroeconomic responses (‘austerity policies’) 
are associated with a significantly higher suicide rate.  
The roles played by family members in supporting someone with 
mental health issues are often hidden from view, yet their unpaid, 
unheralded inputs can often be fundamental to the achievement of a 
better quality of life. The effects on family members themselves can be 
considerable, and so an increasingly visible public policy theme is the 
need to support family carers through information, funding, respite 
services or family-focused therapies. 
Policy needs to address the wide-ranging and durable impacts of 
many mental health problems, which in turn should imply better co-
ordination of local policy and frontline practice responses to ensure that 
individuals do not ‘fall through the net’ or get conflicting advice from 
different agencies. There also needs to be a willingness among policy-
makers to invest for the longer-term, notwithstanding the almost 
universal political reluctance to make such commitments.  
Another important policy theme is to address the pervasive stigma 
experienced by people with mental health problems, and how it 
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manifests itself in discrimination in the workplace, education, social 
relations, citizenship, and participation. Mental health problems are 
disabilities, and should therefore be treated in a similar way to physical 
conditions, but they are also different from those conditions in the extent 
to which people with them are vilified, ostracized and discriminated 
against. Mental health problems are associated with economic and social 
disadvantage, with causal connections potentially flowing in both 
directions. Consequently, public policy in the area of inequalities should 
pay particular attention to mental health problems, while public policy in 
the mental health area should pay particular attention to the risk of social 
and economic marginalization.  
Employment is a key element in all of this, given the social and 
economic benefits that flow from it. Public policy should engage with the 
challenges that people with mental health problems face in trying to get a 
job and keeping it; and also encourage employers to pay attention to the 
wellbeing and mental health needs of their workforce. This may require 
economic incentives, particularly in small and medium-sized enterprises.  
Successful population-wide anti-poverty policies will have benefits 
for people with mental health problems, but there may also be a need for 
targeted action that recognizes the particular vulnerabilities of people 
with longer-term morbidity. This is another example of the need to take 
action across a number of conventional sector boundaries, for instance in 
housing, education, employment, welfare benefits and taxation policy. 
Seeing health – and therefore mental health – as part of an anti-poverty 
strategy has been emphasized by bodies such as the WHO but has 
generally not yet taken root in many low- or middle-income countries.  
Financing mechanisms for mental health vary enormously across the 
world, with out-of-pocket payments still dominating in low-income 
countries, even though these are neither efficient nor equitable In middle-
income and high-income countries, pre-payment mechanisms based on 
taxation, social health insurance or private health insurance tend to 
dominate,  but can still have their limitations when looking at mental 
health needs and treatments. This in part explains the wide gap between 
prevalence and treatment across most of the world, since mental health 
interventions are funded to highly varying degrees. ‘No health without 
mental health’ has become such a common slogan as to have become 
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clichéd, but it reflects the strong view that mental health needs and 
services have been neglected for too long, especially in most low- and 
middle-income countries.  
Discussions of the economic arguments for mental health 
interventions should mirror discussions in any other health or indeed 
other field in terms of relevant criteria and methods. However, some of 
those methods may not be easily applied in the mental health context, 
with the result that mental health interventions may face disadvantages in 
trying to get themselves established.  
7.   Concluding Comments 
As we have demonstrated, most mental health problems are 
complicated and can have many negative and often distressing 
consequences for individuals who are unwell, their families, and the 
wider society. This complexity can make mental illness appear 
‘expensive’, and the durability and wide sphere of impact of many 
conditions add to the economic consequences. Given the pervasive 
scarcity of healthcare and other resources, decision-makers will want to 
think through the economic case for strategies or treatments that might 
address mental health needs.  
What we have just written in the above paragraph could probably be 
applied to many health problems, but mental illness tends to be different. 
What is distinctive is a troublesome combination of interconnected 
challenges: onset at a key life-stage; chronicity; absence of a cure; 
widespread personal shame and public stigma; discrimination in many 
areas of life; impaired capacity during acute phases of illness; close links 
to suicide and self-harm; associations with dangerous behavior (even if 
often exaggerated in the media); and restrictions to individual choice and 
liberty because of assumed or ascribed incapacity or dangerousness. 
These features ought to stimulate searches by all affected parties for 
effective prevention and early intervention, better treatments that are 
more widely accessible and better coordination of actions, both across 
different sectors and over the life-course. Paying attention to the 
economic consequences is obviously essential. 
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